Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition

K. Horackova, M. Janatova, P. Kleiblova, Z. Kleibl, J. Soukupova

. 2023 ; 24 (23) : . [pub] 20231130

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000572

Grantová podpora
NU20-03-00016 Ministry of Health
NU20-09-00355 Ministry of Health
NU23-03-00150 Ministry of Health
RVO-VFN 00064165 Ministry of Health
COOPERATIO Charles University
SVV260516 Charles University
LX22NPO05102 Ministry of Education Youth and Sports

Ovarian cancer (OC) is one of the leading causes of cancer-related deaths in women. Most patients are diagnosed with advanced epithelial OC in their late 60s, and early-onset adult OC diagnosed ≤30 years is rare, accounting for less than 5% of all OC cases. The most significant risk factor for OC development are germline pathogenic/likely pathogenic variants (GPVs) in OC predisposition genes (including BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, Lynch syndrome genes, or BRIP1), which contribute to the development of over 20% of all OC cases. GPVs in BRCA1/BRCA2 are the most prevalent. The presence of a GPV directs tailored cancer risk-reducing strategies for OC patients and their relatives. Identification of OC patients with GPVs can also have therapeutic consequences. Despite the general assumption that early cancer onset indicates higher involvement of hereditary cancer predisposition, the presence of GPVs in early-onset OC is rare (<10% of patients), and their heritability is uncertain. This review summarizes the current knowledge on the genetic predisposition to early-onset OC, with a special focus on epithelial OC, and suggests other alternative genetic factors (digenic, oligogenic, polygenic heritability, genetic mosaicism, imprinting, etc.) that may influence the development of early-onset OC in adult women lacking GPVs in known OC predisposition genes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000572
003      
CZ-PrNML
005      
20240213093252.0
007      
ta
008      
240109s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms242317020 $2 doi
035    __
$a (PubMed)38069345
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Horackova, Klara $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000273904751
245    10
$a Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition / $c K. Horackova, M. Janatova, P. Kleiblova, Z. Kleibl, J. Soukupova
520    9_
$a Ovarian cancer (OC) is one of the leading causes of cancer-related deaths in women. Most patients are diagnosed with advanced epithelial OC in their late 60s, and early-onset adult OC diagnosed ≤30 years is rare, accounting for less than 5% of all OC cases. The most significant risk factor for OC development are germline pathogenic/likely pathogenic variants (GPVs) in OC predisposition genes (including BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, Lynch syndrome genes, or BRIP1), which contribute to the development of over 20% of all OC cases. GPVs in BRCA1/BRCA2 are the most prevalent. The presence of a GPV directs tailored cancer risk-reducing strategies for OC patients and their relatives. Identification of OC patients with GPVs can also have therapeutic consequences. Despite the general assumption that early cancer onset indicates higher involvement of hereditary cancer predisposition, the presence of GPVs in early-onset OC is rare (<10% of patients), and their heritability is uncertain. This review summarizes the current knowledge on the genetic predisposition to early-onset OC, with a special focus on epithelial OC, and suggests other alternative genetic factors (digenic, oligogenic, polygenic heritability, genetic mosaicism, imprinting, etc.) that may influence the development of early-onset OC in adult women lacking GPVs in known OC predisposition genes.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a genetická predispozice k nemoci $7 D020022
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    _2
$a protein BRCA1 $x genetika $7 D019313
650    _2
$a geny BRCA2 $7 D024522
650    12
$a nádory vaječníků $x patologie $7 D010051
650    _2
$a epiteliální ovariální karcinom $x genetika $7 D000077216
650    _2
$a rizikové faktory $7 D012307
650    _2
$a zárodečné mutace $7 D018095
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Janatova, Marketa $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000328166769
700    1_
$a Kleiblova, Petra $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000248069854 $7 xx0125463
700    1_
$a Kleibl, Zdenek $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000320509667 $7 jo2003183974
700    1_
$a Soukupova, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000324131542 $7 xx0239539
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 24, č. 23 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38069345 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093249 $b ABA008
999    __
$a ok $b bmc $g 2049313 $s 1210266
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 23 $e 20231130 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a NU20-03-00016 $p Ministry of Health
GRA    __
$a NU20-09-00355 $p Ministry of Health
GRA    __
$a NU23-03-00150 $p Ministry of Health
GRA    __
$a RVO-VFN 00064165 $p Ministry of Health
GRA    __
$a COOPERATIO $p Charles University
GRA    __
$a SVV260516 $p Charles University
GRA    __
$a LX22NPO05102 $p Ministry of Education Youth and Sports
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...